Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
| ▸ | ALPL | P05186 | 10/20 | 0.54 |
| ▸ | RAB9A | P51151 | 3/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 5/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 2/20 | 0.41 |
| ▸ | CA1 | P00915 | 2/20 | 0.41 |
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
| ▸ | CA9 | Q16790 | 2/20 | 0.41 |
| ▸ | HPGDS | O60760 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3217260 | 0.92 | ALPL (0.64) | MAPK1ALPLRAB9ANPC1GAA | |
| SCHEMBL17479592 | 0.87 | MAPK1 (0.62) | MAPK1ALPLRAB9ANPC1GAA | |
| SCHEMBL7230719 | 0.83 | MAPK1 (0.60) | MAPK1ALPLRAB9ANPC1GAA | |
| SCHEMBL3202467 | 0.83 | MAPK1 (0.60) | MAPK1ALPLRAB9ANPC1GAA | |
| SCHEMBL7998000 | 0.82 | MAPK1 (0.53) | MAPK1ALPLRAB9ANPC1GAA | |
| SCHEMBL30107039 | 0.80 | MAPK1 (0.70) | MAPK1ALPLRAB9ANPC1GAA | |
| SCHEMBL16445052 | 0.78 | MAPT (0.50) | MAPK1ALPLRAB9ANPC1GAA | |
| SCHEMBL26927238 | 0.77 | MAPK1 (0.50) | MAPK1ALPLRAB9ANPC1GAA | |
| SCHEMBL5111954 | 0.77 | GAA (0.56) | MAPK1ALPLRAB9ANPC1GAA | |
| SCHEMBL22574774 | 0.77 | MAPT (0.49) | MAPK1ALPLRAB9ANPC1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080051418-A1 | Arylalkanoic Acid Derivative | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-02-28 | — | — | US | disclosed |
| EP-1829863-A1 | ARYLALKANOIC ACID DERIVATIVE | Takeda Pharmaceutical Company Limited (JP) | 2007-09-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080051418-A1 | Arylalkanoic Acid Derivative | INSR, NPY1R, GPR119 | MAPK1 2249/4885ALPL 4260/4885RAB9A 3734/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.